CoChat

CXCR2 inhibition enables NASH-HCC immunotherapy

Open access
Leslie, Jack, Mackey, John B G, Jamieson, Thomas, Ramon-Gil, Erik, Drake, Thomas M, Fercoq, Frédéric, Clark, William, Gilroy, Kathryn, Hedley, Ann, Nixon, Colin, Luli, Saimir, Laszczewska, Maja, Pinyol, Roser, Esteban-Fabró, Roger, Willoughby, Catherine E, Haber, Philipp K, Andreu-Oller, Carmen, Rahbari, Mohammad, Fan, Chaofan, Pfister, Dominik, Raman, Shreya, Wilson, Niall, Müller, Miryam, Collins, Amy, Geh, Daniel, Fuller, Andrew, McDonald, David, Hulme, Gillian, Filby, Andrew, Cortes-Lavaud, Xabier, Mohamed, Noha-Ehssan, Ford, Catriona A, Raffo Iraolagoitia, Ximena L, McFarlane, Amanda J, McCain, Misti V, Ridgway, Rachel A, Roberts, Edward W, Barry, Simon T, Graham, Gerard J, Heikenwälder, Mathias, Reeves, Helen L, Llovet, Josep M, Carlin, Leo M, Bird, Thomas G, Sansom, Owen J, Mann, Derek A · 2022 · Gut
Cited by 220

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Objective: Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint inhibition (ICI). We hypothesised that targeting neutrophils using a CXCR2 small molecule inhibitor may sensitise NASH-HCC to ICI therapy. Design: Neutrophil infiltration was characterised in human HCC and mouse models of HCC. Late-stage intervention with anti-PD1 and/or a CXCR2 inhibitor was performed in murine models of NASH-HCC. The tumour immune microenvironment was characterised by imaging mass cytometry, RNA-seq and flow cytometry. Results: Neutrophils expressing CXCR2, a receptor crucial to neutrophil recruitment in acute-injury, are highly represented in human NASH-HCC. In models of NASH-HCC lacking response to ICI, the combination of a CXCR2 antagonist with anti-PD1 suppressed tumour burden and extended survival. Combination therapy increased intratumoural XCR1 + dendritic cell activation and CD8 + T cell numbers which are associated with anti-tumoural immunity, this was confirmed by loss of therapeutic effect on genetic impairment of myeloid cell recruitment, neutralisation of the XCR1-ligand XCL1 or depletion of CD8 + T cells. Therapeutic benefit was accompanied by an unexpected increase in tumour-associated neutrophils (TANs) which switched from a protumour to anti-tumour progenitor-like neutrophil phenotype. Reprogrammed TANs were found in direct contact with CD8 + T cells in clusters that were enriched for the cytotoxic anti-tumoural protease granzyme B. Neutrophil reprogramming was not observed in the circulation indicative of the combination therapy selectively influencing TANs. Conclusion: CXCR2-inhibition induces reprogramming of the tumour immune microenvironment that promotes ICI in NASH-HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2021-326259

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 220

Metadata

Authors
Leslie, J., Mackey, J. B. G., Jamieson, T., Ramon-Gil, E., Drake, T. M., Fercoq, F., Clark, W., Gilroy, K., Hedley, A., Nixon, C., Luli, S., Laszczewska, M., Pinyol, R., Esteban-Fabró, R., Willoughby, C. E., Haber, P. K., Andreu-Oller, C., Rahbari, M., Fan, C., Pfister, D., Raman, S., Wilson, N., Müller, M., Collins, A., Geh, D., Fuller, A., McDonald, D., Hulme, G., Filby, A., Cortes-Lavaud, X., Mohamed, N.-E., Ford, C. A., Raffo Iraolagoitia, X. L., McFarlane, A. J., McCain, M. V., Ridgway, R. A., Roberts, E. W., Barry, S. T., Graham, G. J., Heikenwälder, M., Reeves, H. L., Llovet, J. M., Carlin, L. M., Bird, T. G., Sansom, O. J., & Mann, D. A.
Venue
Gut
Publisher
BMJ
Published
2022-04-27
Volume
71
Issue
10
Pages
2093-2106
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4226052234
Cited by
220
References
20
FWCI
16.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CXCR2 inhibition enables NASH-HCC immunotherapy. https://app.cochat.ai/papers/10.1136/gutjnl-2021-326259
The paper
Leslie, J., Mackey, J. B. G., Jamieson, T., Ramon-Gil, E., Drake, T. M., Fercoq, F., Clark, W., Gilroy, K., Hedley, A., Nixon, C., Luli, S., Laszczewska, M., Pinyol, R., Esteban-Fabró, R., Willoughby, C. E., Haber, P. K., Andreu-Oller, C., Rahbari, M., Fan, C., . . . Mann, D. A. (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. https://doi.org/10.1136/gutjnl-2021-326259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.